BioSpace News Archive

MiMedx Group, Inc., a transformational placental biologics company, announced receiving a $4.6 Million award to evaluate PURION® processed Dehydrated Human Amnion Chorion Membrane as an advanced treatment option for wound and burn care.

Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai recently announced the creation of the Center for Engineering and Precision Medicine, one of the first centers in the nation to bridge engineering and engineering science with medicine.

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will present at the 2022 Jefferies Global Healthcare Conference that will be held in New York City on Thursday, June 9, 2022, at 8:00 am ET.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that it will host an Innovation Day focused on early research and development on Tuesday, June 21, 2022 at 2:00 PM ET.

Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose.

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patient care.

VolitionRx Limited has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in more than 27 countries across Europe.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association 2022 Congress taking place in Vienna, Austria, June 9-12.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007.

Endeavor BioMedicines, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor’s clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile.